蓝十字与蓝盾协会将覆盖Interpace公司用于诊断甲状腺癌的MDx检测技术

  Interpace诊断公司今日宣布，独立的蓝十字蓝盾计划(BCBS)将开始覆盖公司的ThyGenX甲状腺癌基因检测盘及进行ThyraMIR甲状腺miRNA分类，这将是进行不确定性甲状腺结节的分子检测手段。
  Interpace诊断作为PDI的子公司，其并不能够确定BCBS计划，但它们却表示可以为330万患者的生命投保，并且首次开展商业性的计划来覆盖ThyraMIR，这项名为ThyraMIR的microRNA基因表达分类系统早在去年已经开始发起用来鉴别不确定性及恶性的甲状腺结节。
  这项业务覆盖决定紧跟最近安泰保险公司对ThyGenX的覆盖，而ThyGenX则是一种新一代的基于测序的基因突变检测盘，其用于对患者的疾病进行风险分类，同时还可以帮助进行外科手术的决定，当标准的细胞病理学并不能为甲状腺癌的诊断提供决定时该技术就可以派上用场。
  最后Interpace公司表示，一项未经确认的简约版国家计划近日将会扩大对额外130万患者进行PancraGen的胰腺囊肿癌症风险的分类检测，从而将使得总的覆盖率测试达到1000万名患者，同时BCBS也将计划更新PancraGen的合同覆盖590万患者，用于改善患者的健康。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

BCBS Plan Covers Interpace MDx Tests for Thyroid Cancer
Interpace Diagnostics today announced that an independent Blue Cross Blue Shield plan has begun covering the firm's ThyGenX Thyroid Oncogene Panel and ThyraMIR Thyroid miRNA Classifier, molecular tests for indeterminate thyroid nodules. 

Interpace, a subsidiary of PDI, did not identify the BCBS plan but said that it insures 3.3 million lives and added that it is the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year for identifying indeterminate benign and malignant thyroid nodules. 

The coverage decision follows a recent similar decision by Aetna to cover ThyGenX, a next-generation sequencing-based gene mutation panel for risk stratification and surgical decision-making. The test is used when standard cytopathology does not provide a clear diagnosis of thyroid cancer. 

Interpace added that an unidentified contracted national plan recently extended coverage of its PancraGen pancreatic cyst cancer risk stratification test to an additional 1.3 million lives, bringing the plan's total covered lives for the test to 10 million. Also, a BCBS plan has renewed PancraGen contract coverage for 5.9 million lives, Interpace said.